GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that develops and markets medicines and vaccines across areas ...

On Thursday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $27.46 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.36. The stock opened at $27.53 and ...

There are two other vaccines already available in Canada to protect seniors against severe illness caused by RSV: Arexvy, ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The Dow Jones Industrial Average's shift away from value and income could open the door for other mega-cap growth stocks.

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Health professionals recommend vaccines before traveling to celebrate the holidays with family. If you missed the early fall ...

STAT's Readout LOUD podcast discusses how Trump's second term and the MAHA movement could affect FDA regulation, the ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...